Profile data is unavailable for this security.
About the company
Kazia Therapeutics Limited is an Australia-based pharmaceutical drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.
- Revenue in USD (TTM)80.18k
- Net income in USD-14.56m
- Incorporated1994
- Employees12.00
- LocationKazia Therapeutics LtdThree International Towers Level 24, 300 Barangaroo AvenueSYDNEY 2000AustraliaAUS
- Phone+61 29472-4100
- Fax+61 29476-0388
- Websitehttps://www.kaziatherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Precision BioSciences Inc | 698.00k | -83.60m | 99.60m | 67.00 | -- | 3.16 | -- | 142.70 | -8.40 | -8.40 | 0.0695 | 1.38 | 0.0057 | -- | 0.9001 | 6,462.96 | -67.76 | -26.22 | -76.07 | -33.68 | -- | -- | -11,977.36 | -87.80 | -- | -190.84 | 0.5736 | -- | 40.98 | 25.30 | 116.85 | -- | -59.31 | -- |
| Turn Therapeutics Inc | -100.00bn | -100.00bn | 101.00m | -- | -- | 190.70 | -- | -- | -- | -- | -- | 0.018 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.85 | -- | -- | -- |
| Gain Therapeutics Inc | 0.00 | -19.39m | 101.16m | 23.00 | -- | 16.01 | -- | -- | -0.6364 | -0.6364 | 0.00 | 0.1643 | 0.00 | -- | -- | 0.00 | -153.07 | -79.58 | -234.03 | -95.32 | -- | -- | -- | -19,975.78 | -- | -33.79 | 0.067 | -- | -100.00 | -- | 8.34 | -- | 10.39 | -- |
| Korro Bio Inc | 7.37m | -88.42m | 101.24m | 87.00 | -- | 1.02 | -- | 13.73 | -9.42 | -9.42 | 0.7855 | 10.54 | 0.0364 | -- | 1.36 | 70,875.00 | -43.65 | -- | -46.92 | -- | -- | -- | -1,199.53 | -- | -- | -- | 0.00 | -- | -- | -- | -2.97 | -- | -- | -- |
| Goldenwell Biotech Inc | 62.50k | -75.13k | 103.95m | -- | -- | -- | -- | 1,663.20 | -0.0007 | -0.0007 | 0.0006 | -0.001 | 0.3126 | 0.00 | -- | -- | -37.58 | -95.49 | -41.82 | -110.12 | 100.00 | 52.18 | -120.21 | -2,064.27 | 1.16 | -4.11 | 124.14 | -- | -92.39 | -13.55 | -12.05 | -- | -- | -- |
| Aardvark Therapeutics Inc | 0.00 | -48.77m | 106.69m | 33.00 | -- | 0.8707 | -- | -- | -2.53 | -2.53 | 0.00 | 5.63 | 0.00 | -- | -- | -- | -44.96 | -- | -47.90 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -185.63 | -- | -- | -- |
| Cassava Sciences Inc | 0.00 | -106.03m | 107.24m | 30.00 | -- | 1.31 | -- | -- | -2.20 | -2.20 | 0.00 | 1.69 | 0.00 | -- | -- | 0.00 | -59.99 | -28.22 | -85.37 | -29.72 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 74.96 | -- | 41.75 | -- |
| Kazia Therapeutics Ltd (ADR) | 80.18k | -14.56m | 107.43m | 12.00 | -- | -- | -- | 1,339.93 | -12.21 | -12.21 | 0.0558 | -3.61 | 0.0083 | -- | 0.0571 | -- | -149.76 | -64.49 | -- | -99.77 | -- | -- | -18,159.65 | -573.31 | -- | -- | -- | -- | -95.09 | 11.58 | 22.69 | -- | -- | -- |
| Equillium Inc | 4.39m | -24.42m | 107.78m | 35.00 | -- | 3.47 | -- | 24.54 | -0.632 | -0.632 | 0.1021 | 0.5099 | 0.1274 | -- | 1.71 | 125,485.70 | -70.81 | -44.86 | -89.09 | -58.85 | -- | -- | -555.94 | -164.30 | -- | -- | 0.00 | -- | 13.89 | -- | 39.51 | -- | 2.81 | -- |
| Gossamer Bio Inc | 44.05m | -156.16m | 108.78m | 144.00 | -- | -- | -- | 2.47 | -0.6872 | -0.6872 | 0.1939 | -0.356 | 0.1574 | -- | 5.57 | 305,909.70 | -55.80 | -51.30 | -69.95 | -58.28 | -- | -- | -354.50 | -822.21 | -- | -15.04 | 1.71 | -- | -- | -- | 68.56 | -- | -- | -- |
| Coya Therapeutics Inc | 3.99m | -18.43m | 109.97m | 8.00 | -- | 2.88 | -- | 27.58 | -1.11 | -1.11 | 0.2397 | 1.63 | 0.118 | -- | -- | 498,462.50 | -54.54 | -- | -59.84 | -- | -- | -- | -462.26 | -- | -- | -- | 0.00 | -- | -40.79 | -- | -86.29 | -- | -- | -- |
| Oncolytics Biotech Inc | 0.00 | -25.79m | 111.91m | 29.00 | -- | 1,281.85 | -- | -- | -0.2868 | -0.2868 | 0.00 | 0.0008 | 0.00 | -- | -- | -- | -179.40 | -75.50 | -293.88 | -87.03 | -- | -- | -- | -- | -- | -- | 0.879 | -- | -- | -- | -14.26 | -- | 85.40 | -- |
| ALX Oncology Holdings Inc | 0.00 | -108.01m | 112.23m | 44.00 | -- | 2.48 | -- | -- | -2.01 | -2.01 | 0.00 | 0.8362 | 0.00 | -- | -- | 0.00 | -80.47 | -37.96 | -103.67 | -40.71 | -- | -- | -- | -46,390.86 | -- | -- | 0.2099 | -- | -- | -- | 16.14 | -- | 4.84 | -- |
| Agenus Inc | 106.83m | -35.38m | 114.93m | 316.00 | -- | -- | -- | 1.08 | -2.09 | -2.09 | 3.94 | -8.35 | 0.4523 | -- | 286.79 | 338,066.50 | -16.63 | -58.29 | -- | -140.29 | 98.93 | 97.31 | -36.77 | -125.67 | -- | -1.17 | 6.78 | -- | -33.81 | -7.17 | 7.54 | -- | -34.16 | -- |
| Genelux Corp | 0.00 | -31.87m | 115.36m | 24.00 | -- | 5.22 | -- | -- | -0.8803 | -0.8803 | 0.00 | 0.4943 | 0.00 | -- | -- | 0.00 | -97.69 | -125.27 | -116.81 | -- | -- | -- | -- | -830.46 | -- | -- | 0.00 | -- | -95.29 | -- | -5.56 | -- | -26.46 | -- |
| Inovio Pharmaceuticals Inc | 182.33k | -108.09m | 115.42m | 134.00 | -- | -- | -- | 633.04 | -2.63 | -2.63 | 0.0046 | -0.1441 | 0.0021 | -- | 0.1283 | 1,360.67 | -122.52 | -58.57 | -260.08 | -70.33 | -- | -- | -59,283.97 | -4,810.90 | -- | -6.49 | -- | -- | -73.83 | -44.44 | 20.62 | -- | -13.16 | -- |
Data as of Mar 03 2026. Currency figures normalised to Kazia Therapeutics Ltd's reporting currency: US Dollar USD
75.14%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Alyeska Investment Group LPas of 31 Dec 2025 | 738.32k | 6.51% |
| Lynwood Capital Management, Inc.as of 15 Jan 2026 | 616.00k | 36.87% |
| Stonepine Capital Management LLCas of 31 Dec 2025 | 460.36k | 4.06% |
| Bleichroeder LPas of 31 Dec 2025 | 400.00k | 3.53% |
| Velan Capital Investment Management LPas of 31 Dec 2025 | 300.00k | 17.96% |
| Point72 Asset Management LPas of 31 Dec 2025 | 200.00k | 1.76% |
| Empery Asset Management LPas of 31 Dec 2025 | 170.00k | 1.50% |
| Corsair Capital Management LPas of 31 Dec 2025 | 70.00k | 0.62% |
| RBC Capital Markets LLC (Investment Management)as of 31 Dec 2025 | 54.13k | 0.48% |
| Westside Investment Management LLCas of 31 Dec 2025 | 30.88k | 1.85% |
More ▼
Data from 31 Dec 2025 - 15 Jan 2026Source: FactSet Research Systems Inc.
